Year-end report October – December 2020
February 24, 2021
Curasight A/S (“Curasight” or “the Company”) hereby publishes the year-end report for the period October 1 – December 31, 2020. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
US patent application 14/399,820 relating to uTREAT[®] is accepted for grant
February 8, 2021
The United States Patent and Trademark Office has issued a notice of allowance confirming that the United States Patent Application no. 14/399,820 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted. The patent will expire May 2033.
Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine
December 21, 2020
As previously communicated in connection with the IPO the results from the phase II study performed by researchers at Rigshospitalet were available in 2020. Following data analysis, a scientific manuscript covering the results has been submitted by the research group to the Journal of Nuclear Medicine where it underwent a stringent peer-review process. Following this process, the manuscript has been accepted for publication in an upcoming issue of the Journal of Nuclear Medicine probably during H1 2021.
Japanese patent application 2019-005811 is accepted for grant
December 16, 2020
The Japan Patent Office has issued a notice of allowance confirming that the Japanese Patent Application no. 2019-005811 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted.
Financial Calendar 2021
December 15, 2020
Curasight A/S (Ticker: CURAS, CURAS T01) today announces that the company expects to publish financial reports according to the following schedule:
Interim report January – September 2020
November 30, 2020
Curasight A/S (“Curasight” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2020. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight initiates pre-clinical study on therapy (uTREAT[®]) in brain cancer and signs CRO-agreement
November 11, 2020
Curasight A/S (“Curasight” or “the Company”) today announces that it has initiated the pre-clinical study of uPAR targeted radionuclide therapy (uTREAT[®]) in brain cancer and signed an agreement with the Danish CRO Minerva Imaging A/S (“Minerva Imaging”), to conduct the pre-clinical study. The initiation of the pre-clinical study is thus in line with previously communicated targets. Minerva Imaging has provided Curasight with a cost-efficient proposal that ensures that the Company’s communicated timelines are kept. Results are, as earlier communicated, expected to be available during 2021.
Canadian patent application relating to uTRACE[®] is ready for allowance in Canada
October 22, 2020
The Canadian Intellectual Property Office has announced that Curasight’s Canadian patent application CA 2,903,261 is ready for allowance and the patent will be issued. This patent application relates to Curasight’s imaging technology relating to uTRACE[®] (imaging agent Ga-NOTA-AE105) and uses thereof until 2034.
First day of trading in Curasight’s shares and warrants at Spotlight Stock Market
October 8, 2020
Today is the first day of trading in Curasight A/S ("Curasight") shares and warrants of series TO 1. Curasight’s shares are traded under the ticker "CURAS" with ISIN DK0061295797 and Curasight’s warrants of series TO 1 are traded under the ticker "CURAS TO 1" with ISIN DK0061408747.
Prolongation and expansion of agreement with TRT Innovations ApS
October 7, 2020
Today, the 7 October, 2020, Curasight A/S (“Curasight” or the “Company”) has entered into an expansion of the agreement with TRT Innovations ApS (“TRT Innovations”), which ensures the right for the Company to broaden its activities within targeted radionuclide therapy in cancer.